Assertion Supported AI assessment confidence: 95% certainty 4/5 debate potential 2/5

Bryan Johnson notes many popular peptides have zero human clinical data

Bryan Johnson · $1M a Year to Live Forever? Bryan Johnson Explains · Feb 12, 2026 · at 20:07

Longevity entrepreneur Bryan Johnson warns TBPN hosts about the safety blind spots in the peptide craze due to a lack of human clinical trials.

0:00 / 0:07exact quote · 7.5s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“Some peptides have done the clinical work, like there's hepatitis, but then there's a whole bunch of the class of peptides that we have no human data on.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

There is no published human clinical trial data for many peptide compounds currently in popular consumer and biohacking use.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Biomedical literature, clinical trial registries, and regulatory reviews confirm that several widely marketed and popular biohacking/consumer research peptides lack completed, peer-reviewed human clinical trial data evaluating safety and efficacy as of February 2026. For example, BPC-157 has extensive preclinical literature but lacked completed Phase II/III human trials, prompting the FDA to place it in compounding Category 2 in September 2023 citing insufficient human safety data. TB-500 (the synthetic thymosin beta-4 fragment) has no completed human trials for consumer applications, and Melanotan II was abandoned in formal clinical drug development following small pilot studies in the 1990s. Regulatory reviews for compounds such as Dihexa, MOTS-c, and KPV similarly document an absence of published human clinical trial safety and pharmacokinetic data.

Systematic reviews in biomedical literature (PMC, July 2025; MDPI, January 2025) note the absence of completed Phase II/III human clinical trials for BPC-157.
The FDA placed BPC-157 in Category 2 for pharmacy compounding in September 2023 due to a lack of human safety information and potential immunogenicity risks.
A 2026 scoping review (MDPI) established that the synthetic fragment sold as TB-500 lacks completed, peer-reviewed human clinical trials in musculoskeletal applications.
FDA bulk drug compounding reviews (2023–2026) document an absence of published human clinical trial and pharmacokinetic data for popular research peptides including Dihexa, KPV, and MOTS-c.

Checked against

[1] nih.gov [2] mdpi.com [3] mdpi.com [4] nih.gov [5] clinicaltrials.gov [6] mcgill.ca [7] fda.gov [8] nih.gov

Melanotan II clinical trials safety human data PubMed TB 500 Thymosin beta 4 human clinical trials BPC 157 human clinical trials PubMed FDA peptide compounding BPC 157 safety human trials Category 2

assessed as of 2026-09-02

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

Bryan Johnson peptides

⚑ Spot an error? Report it

More from Bryan Johnson

Assertion Not checkable as stated

Bryan Johnson says organic products typically test worse than non-organic foods

“When we test organic, It typically performs worse than non-organic on many, many variables.”

Bryan Johnson Feb 12, 2026 ▶ 9:38 $1M a Year to Live Forever? Bryan Johnson Explains

Prediction Not checkable as stated

Bryan Johnson predicts 'Don't Die' will become the world's dominant ideology

“Our primary hypothesis is as this evolves, the major shift is humans are going to want life. Like, you know, if AI takes our jobs and they take what we do and we want to find new identity, there's going to be a major shift towards don't die. And it's going to …”

Bryan Johnson Feb 12, 2026 ▶ 13:07 $1M a Year to Live Forever? Bryan Johnson Explains

Prediction Not checkable as stated

Bryan Johnson predicts Blueprint's platform will exceed the FDA in value

“I think that we will exceed them in value in many core areas. Because they, you, they can take, you know, well-structured, well-funded clinical trials. But then other things like peptides that are very promising. They're not going to have the clinical work.”

Bryan Johnson Feb 12, 2026 ▶ 22:18 $1M a Year to Live Forever? Bryan Johnson Explains

Disclosure

Bryan Johnson launches Immortals, a $1 million per year personal longevity program

“So it's called Immortals. A million dollars a year. And it's my exact protocol. So my doctors, my concierge team, all the testing infrastructure.”

Bryan Johnson Feb 12, 2026 ▶ 3:49 $1M a Year to Live Forever? Bryan Johnson Explains

Prediction Not checkable as stated

Bryan Johnson: Humanity Is Giving Birth to Superintelligence

“We are giving birth to some kind of super intelligence. We don't know what it is. We don't know what kind of scale, but it's big. It's important.”

Bryan Johnson Oct 30, 2025 ▶ 3:50 Don't Die CEO Bryan Johnson on Living Forever, AI & His $60M Blueprint For Immortality

Opinion

Johnson: Project Blueprint is fundamentally about AI alignment

“What a lot of people don't realize is this endeavor is entirely about AI alignment.”

Bryan Johnson Oct 30, 2025 ▶ 4:41 Don't Die CEO Bryan Johnson on Living Forever, AI & His $60M Blueprint For Immortality

Bryan Johnson notes many popular peptides have zero human clinical data

More from Bryan Johnson

Turn any episode into a week of clips.